Research ArticleOncology
Open Access
Immuno-PET Imaging to Assess Target Engagement: Experience from 89Zr-Anti-HER3 mAb (GSK2849330) in Patients with Solid Tumors
C. Willemien Menke-van der Houven van Oordt, Adam McGeoch, Mats Bergstrom, Iain McSherry, Deborah A. Smith, Matthew Cleveland, Wasfi Al-Azzam, Liangfu Chen, Henk Verheul, Otto S. Hoekstra, Danielle J. Vugts, Immanuel Freedman, Marc Huisman, Chris Matheny, Guus van Dongen and Sean Zhang
Journal of Nuclear Medicine July 2019, 60 (7) 902-909; DOI: https://doi.org/10.2967/jnumed.118.214726
C. Willemien Menke-van der Houven van Oordt
1Department of Medical Oncology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, The Netherlands
Adam McGeoch
2Division of Experimental Medicine and Immunotherapeutics, Department of Medicine, University of Cambridge, Cambridge, United Kingdom
Mats Bergstrom
3OMID Molecular Imaging Consultancy, Uppsala, Sweden
Iain McSherry
4Clinical Pharmacology, Science, and Study Operations, GlaxoSmithKline, Uxbridge, United Kingdom
Deborah A. Smith
5Clin Pharm Advantage, LLC, Durham, North Carolina
Matthew Cleveland
6Bioimaging, Platform Technology and Science, GlaxoSmithKline, Stevenage, United Kingdom
Wasfi Al-Azzam
7Biopharm Product Development and Supply, GlaxoSmithKline, King of Prussia, Pennsylvania
Liangfu Chen
8Drug Metabolism and Pharmacokinetics, GlaxoSmithKline, King of Prussia, Pennsylvania
Henk Verheul
1Department of Medical Oncology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, The Netherlands
Otto S. Hoekstra
9Department of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
Danielle J. Vugts
9Department of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
Immanuel Freedman
10Freedman Patent, Harleysville, Pennsylvania
Marc Huisman
9Department of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
Chris Matheny
11Oncology R&D, GlaxoSmithKline, King of Prussia, Pennsylvania; and
Guus van Dongen
9Department of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
Sean Zhang
12Hengrui Therapeutics, Inc., Princeton, New Jersey
Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 60, Issue 7
July 1, 2019
Immuno-PET Imaging to Assess Target Engagement: Experience from 89Zr-Anti-HER3 mAb (GSK2849330) in Patients with Solid Tumors
C. Willemien Menke-van der Houven van Oordt, Adam McGeoch, Mats Bergstrom, Iain McSherry, Deborah A. Smith, Matthew Cleveland, Wasfi Al-Azzam, Liangfu Chen, Henk Verheul, Otto S. Hoekstra, Danielle J. Vugts, Immanuel Freedman, Marc Huisman, Chris Matheny, Guus van Dongen, Sean Zhang
Journal of Nuclear Medicine Jul 2019, 60 (7) 902-909; DOI: 10.2967/jnumed.118.214726
Immuno-PET Imaging to Assess Target Engagement: Experience from 89Zr-Anti-HER3 mAb (GSK2849330) in Patients with Solid Tumors
C. Willemien Menke-van der Houven van Oordt, Adam McGeoch, Mats Bergstrom, Iain McSherry, Deborah A. Smith, Matthew Cleveland, Wasfi Al-Azzam, Liangfu Chen, Henk Verheul, Otto S. Hoekstra, Danielle J. Vugts, Immanuel Freedman, Marc Huisman, Chris Matheny, Guus van Dongen, Sean Zhang
Journal of Nuclear Medicine Jul 2019, 60 (7) 902-909; DOI: 10.2967/jnumed.118.214726